A Real World Study to Evaluate the Efficacy and Safety of First Line Crizotinib in ALK Rearranged Advanced Non Squamous Non-small Cell Lung Cancer
Phase of Trial: Phase IV
Latest Information Update: 01 Feb 2019
Price : $35 *
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 23 Jan 2019 Planned End Date changed from 1 Jun 2019 to 1 Dec 2020.
- 23 Jan 2019 Planned primary completion date changed from 31 Dec 2018 to 31 Dec 2019.
- 03 Sep 2018 New trial record